Wyeth Europa: European Commission Approval Makes Enbrel(R) First and Only Biologic Treatment Approved for Severe Psoriasis in Paediatric Patients

Maidenhead, England (ots/PRNewswire) -

- For the First Time, Children and Adolescents in Europe With
Psoriasis are now Able to Benefit From Same Efficacy and Disease
Control as Adults

The European Commission today granted marketing authorisation of
the use of Enbrel(R) (etanercept) as the first biologic licensed for
treatment in children and adolescents with chronic severe plaque
psoriasis. The approval by the Commission allows for the treatment of
patients between the ages of eight and 17(1) who are inadequately
controlled by, or are intolerant to, other systemic therapies or
phototherapies. The approval follows a positive recommendation from
the Committee for Medicinal Products for Human Use in November 2008
and is based on the results from the 211 study, the first trial of a
biologic treatment in plaque psoriasis patients in this age group.
This is the sixth indication for Enbrel which is also approved for
use in adult rheumatoid arthritis, juvenile idiopathic arthritis,
ankylosing spondylitis, adult psoriatic arthritis and adult
psoriasis.

"We are delighted by the news of the European Commission's
approval of the use of Enbrel in this younger population which up
until now, were unable to access the same treatment options that
adults with psoriasis have had for four years," said Andreas Krebs,
President, Wyeth Europe. "Enbrel has a long established efficacy and
safety record, with 16 years of collective clinical experience. This
approval makes Enbrel the first and only biologic psoriasis treatment
licensed for children aged eight to 17 and solidifies Enbrel's
position as the leading psoriasis treatment."

More than a skin disease

Across Europe, 5.1 million people are estimated to have
psoriasis(2), a distressing chronic inflammatory disease.
Approximately 80 per cent of these patients have plaque psoriasis(3),
which is characterised by red, scaly patches. But psoriasis is more
than just a skin disease and can have a significant impact on
patients' quality of life. A third of psoriasis patients first see
signs of the disease in childhood,(4) when they may experience
feelings of embarrassment over the appearance of their skin and
anxiety about rejection from peers.(5)

Enbrel is effective in children

Results from the 211 study showed that at 12 weeks, 57% of
patients receiving Enbrel achieved 75% improvement in the psoriasis
area-and-severity index (PASI 75) compared to 11% of the patients
receiving placebo. After 36 weeks, 68% of Enbrel patients achieved
PASI 75.(6) Enbrel was found to be well tolerated.

"The approval of Enbrel for severe childhood psoriasis offers an
important new treatment option for the control of psoriasis at an
age, where only few other treatment modalities are available," said
Professor Jörg Prinz from the Department of Dermatology at the
Ludwig-Maximillians University in Munich, Germany. "Enbrel is an
innovative drug that works by reducing the chronic inflammation that
leads to plaque psoriasis. It allows physicians to target psoriatic
inflammation at its roots and if used appropriately, offers these
young patients the possibility of clear skin and an improved quality
of life when other treatments have failed."

Enbrel was the first biologic treatment in Europe for adults with
moderate to severe plaque psoriasis when approved in 2004. Enbrel was
also the first approved treatment for polyarticular juvenile
arthritis in children and adolescents aged four to 17 years
(receiving approval in 1999 both in the US and European Union).(1)

To access further media information relating to this press
release, additional information on Enbrel and future media
announcements, please register on the media centre at
http://www.wyeth.eu. If you subscribe to receive our emails you will
get updates as soon as new content is added to the site. Please note
you will be able to unsubscribe at any time and we will not pass your
details on to any third party.

NOTES TO EDITORS

The 211 study: Enbrel(R) in children and adolescents(6)

The 48 week study involved 211 patients with moderate-to-severe
psoriasis between the ages of four and 17 years. During the first 12
weeks of the trial, patients received once weekly injections of
either placebo or 0.8mg of Enbrel per kilogram of body weight. All
patients then received Enbrel for 24 consecutive weeks. At week 36,
138 patients were randomised to receive placebo or Enbrel to
investigate the effects of stopping and re-starting treatment.

At week 12, almost two-thirds (57%) of patients achieved a 75%
improvement in the psoriasis area-and-severity index (PASI 75),
compared to 11% of patients receiving placebo. At week 36, after 24
weeks of open-label Enbrel, 68% of patients in the Enbrel-Enbrel
group and 65% of patients in the placebo-Enbrel group achieved PASI
75. During the treatment withdrawal period, 42% of patients receiving
placebo instead of Enbrel, lost their response to treatment.

There were no serious adverse events or serious infections during
the 12-week placebo-controlled period and rates of adverse events
were similar for Enbrel and placebo. During open-label treatment,
three patients developed four serious adverse events. No deaths,
cancers, opportunistic infections, tuberculosis or demyelination
events were reported. The most common adverse events observed during
the 48-week trial in patients treated with Enbrel were upper
respiratory tract infection, headache, and nasopharyngitis.

ABOUT ENBREL

Enbrel is a fully human soluble tumour necrosis factor (TNF)
receptor. Enbrel was first approved in 1998 for moderate to severe
rheumatoid arthritis and has since been used in nearly 500,000
patients worldwide across indications.

Enbrel in the EU is approved for the following indications:

Rheumatoid arthritis

Enbrel in combination with methotrexate is indicated for the
treatment of moderate to severe active rheumatoid arthritis in adults
when the response to disease-modifying antirheumatic drugs, including
methotrexate (unless contraindicated), has been inadequate.

Enbrel can be given as monotherapy in case of intolerance to
methotrexate or when continued treatment with methotrexate is
inappropriate.

Enbrel is also indicated in the treatment of severe, active and
progressive rheumatoid arthritis in adults not previously treated
with methotrexate.

Enbrel, alone or in combination with methotrexate, has been shown
to reduce the rate of progression of joint damage as measured by
X-ray and to improve physical function.

Polyarticular juvenile idiopathic arthritis

Treatment of active polyarticular juvenile idiopathic arthritis
in children and adolescents aged 4 to 17 years who have had an
inadequate response to, or who have proved intolerant of,
methotrexate. Enbrel has not been studied in children aged less than
4 years.

Psoriatic arthritis

Treatment of active and progressive psoriatic arthritis in adults
when the response to previous disease-modifying antirheumatic drug
therapy has been inadequate. Enbrel has been shown to improve
physical function in patients with psoriatic arthritis, and to reduce
the rate of progression of peripheral joint damage as measured by
X-ray in patients with polyarticular symmetrical subtypes of the
disease.

Ankylosing spondylitis

Treatment of adults with severe active ankylosing spondylitis who
have had an inadequate response to conventional therapy.

Plaque psoriasis

Treatment of adults with moderate to severe plaque psoriasis who
failed to respond to, or who have a contraindication to, or are
intolerant to other systemic therapy including cyclosporine,
methotrexate or PUVA.

ABOUT WYETH:

Wyeth is one of the world's largest research-based pharmaceutical
and health care products companies. It is a leader in the discovery,
development, manufacturing, and marketing of prescription drugs and
over-the-counter medications. It is also a global leader in vaccines,
biotechnology and animal health care.

REFERENCES
1. Enbrel EMEA SPC.
http://www.emea.europa.eu/humandocs/PDFs/EPAR/Enbrel/H-262-PI-en.pdf
2. Christophers E. Psoriasis - Epidemiology and Clinical Spectrum. Clin
Exp Dermatol 2001;26:314-320
3. National Psoriasis Foundation. Plaque Psoriasis.
http://www.psoriasis.org/about/psoriasis/plaque.php Accessed October
2008
4. National Psoriasis Foundation. Medical facts about psoriasis in
childhood. http://www.psoriasis.org/about/youth/parents/medicalfacts.php
Accessed October 2008
5. National Psoriasis Foundation. Emotional effects of psoriasis on
children. http://www.psoriasis.org/about/youth/parents/children.php
Accessed October 2008
6. Paller, AS et al. Etanercept treatment for children and adolescents
with plaque psoriasis. N Engl J Med 2008;358:241-51

ots Originaltext: Wyeth Europa
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information, please contact: Wyeth: Gill Markham,
Communications - Europe, Middle East and Africa, Direct Tel:
+44-1628-692536, Email: markhagl@wyeth.com; Danielle Halstrom,
Communications - Global, Direct Tel: +1-484-865-2020, Email:
halstrd@wyeth.com; OgilvyHealthPR: Mary Barrington-Ward, Tel:
+44-207-108-6066, Email: mary.barrington-ward@ohpr.com